ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
31 janv. 2024 07h57 HE
|
ZyVersa Therapeutics
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
30 janv. 2024 08h05 HE
|
DSS, Inc.
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative...
Airfinity launches world’s first obesity data and analytics platform
24 janv. 2024 04h57 HE
|
Airfinity
London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market. ...
WeightWatchers Unveils “Beyond Hunger: Understanding Food Noise” Report Offering Insights Into the Experience of Ongoing, Intrusive Thoughts About Food
16 janv. 2024 09h16 HE
|
WW International Inc.
Findings of WeightWatcher's “Beyond Hunger: Understanding Food Noise” report, focus on the experience of people living with "food noise".
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
08 janv. 2024 15h45 HE
|
Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
05 janv. 2024 07h48 HE
|
Fractyl Health, Inc.
FRACTYL HEALTH ANNOUNCES NOMINATION OF RJVA-001 AS FIRST CLINICAL CANDIDATE IN ITS REJUVA® GLP-1 GENE THERAPY PLATFORM
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
05 janv. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist
Global Obesity Drugs and Delivery Platforms Market Research Report 2023: GLP-1-based Drugs, Along With Injector and Nanomaterial Delivery Platforms, Drive Transformational Industry Growth
05 janv. 2024 06h08 HE
|
Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Obesity Drugs and Delivery Platforms" report has been added to ResearchAndMarkets.com's offering. In this study, the...
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
02 janv. 2024 02h00 HE
|
Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
14 déc. 2023 05h45 HE
|
Fractyl Health, Inc.
Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain